The exact mechanisms for the selective toxicity of chemotherapeutic drugs against tumor cells are not fully understood. We designed a series of experiments to test the possibility that the positive proliferative signal initiated by oncogenes might change the sensitivity for apoptosis induction by the anticancer drug etoposide (VP16), an inhibitor of topoisomerase II (Topo II). Treatment with VP16 induced signi®cantly increased apoptosis in NIH3T3 cells transformed by oncogenic src, ras or raf, compared with the normal 3T3 cells. Apopototic changes involved nuclear DNA fragmentation, morphological alterations and decreased viability. Furthermore it was shown that stress-activated protein kinase (SAPK) was activated much more strongly in all three transformed lines compared to untransformed cells by VP16 treatment, while slight activation of extracellular signal-regulated kinase (ERK1) was observed in all four cell lines. In addition, the transformed cells displayed arrest in mid-S-phase following the treatment, whereas NIH3T3 cells were primarily arrested in late S and G 2 /M phase. Finally, the cyclin-dependent kinase inhibitor p21 WAF1 was induced in all four cell lines, although induction of p53 was not detected in any of these cell lines. Taken together our results demonstrated that oncogenic transformation can sensitize the cells to apoptosis induction, stress kinase activation and cell cycle arrest in response to VP16 treatment. These results may have important implications for understanding the selective toxicity of anti-cancer drugs in tumor cells.
Introduction
A variety of explanations for the selective toxicity of tumor cells by chemotherapeutic treatments has been proposed. Classically, such treatments were believed to selectively kill rapidly dividing cells, although it is now becoming clear that susceptible tumors can be relatively slow growing, while many rapidly dividing cancers are resistant to chemotherpy (Fisher, 1994) . Oncogenic transformation by c-myc is known to sensitize cells to apoptosis induced by various stimuli (Bissonnette et al., 1992; Fanidi et al., 1992; Hermeking and Eick, 1994) . A similar phenomenon has also been observed in E1A transformed cells (Teodoro et al., 1995; Lowe et al., 1993 Lowe et al., , 1994 . This apoptosis development can occur in a p53-dependent (Hermeking and Eick, 1994; Teodoro et al., 1995; Lowe et al., 1994) and in a p53-independent way (Teodoro et al., 1995) , and is inhibited by bcl-2 (Bissonnette et al., 1992; Fanidi et al., 1992) . Since most cancer drugs can induce apoptosis (Fisher, 1994; Thompson, 1995; Hickman, 1992; Kerr et al., 1994) , these results might indicate that oncogenes might function to decrease the threshold for apoptosis in tumor cells (Fisher, 1994) . This idea would suggest that one or a set of genes altered during tumor formation would increase the likelihood of apoptosis following drug treatment.
Among the many genes mutated in spontaneous tumors, several of the dominantly acting oncogenes are derived from the proliferative signaling pathway. These include the tyrosine kinase src, the small G-protein ras and the serine/threonine kinase raf. These three genes are representatives of classes of genes which act in a generally sequential fashion in proliferative signal transduction (Denhardt, 1996) . The action of these proliferative signaling molecules ultimately leads to the activation of kinases, including mitogen-activated protein kinases (MAPKs) such as the extracellularsignal-regulated kinases (ERKs), stress activated protein kinase (SAPK; also called jun kinase or JNK), and the p38 subfamily (Kyriakis and Avruch, 1996) . While ERKs, which are most eciently stimulated by growth factors and phorbol esters, SAPK activity is stimulated by protein synthesis inhibitors, DNA damaging agents and physical stress (Cano and Mahadevan, 1995; Karin, 1995) . The activation of SAPK requires the phosphorylation of both tyrosine and threonine by a dual speci®city protein kinase Minden et al., 1994) . Active SAPK phosphorylates the NH2-terminal activation domain of the c-Jun protein, leading to increased transcriptional activity (Franklin et al., 1992; Hibi et al., 1993) . Other nuclear transcriptional factors have also been recently identi®ed as SAPK targets (Gupta et al., 1995; Whitmarsh et al., 1995) . While the biological consequence of SAPK activation has not been clari®ed in detail, recent studies suggested that its activation contributes signi®cantly to apoptosis development in some cell lines (Verheij et al., 1996; Cuvillier et al., 1996; Xia et al., 1995) . Ras has been demonstrated to activate SAPK in some instances (Smeal et al., 1991; Clark et al., 1997) and mediate tumor necrosis factor (TNF) induced apoptosis (Trent et al., 1996) . It is therefore possible that the action of oncogenes might enhance the response of SAPK to stressful stimuli.
Progression of the eukaryotic cell division cycle is strictly regulated by a set of proteins which direct the cell towards proliferation, growth inhibition or apoptosis. Critical among these are cyclins D and E, together with their dependent kinases (cdk) and associated cyclin inhibitory proteins including p21WAF1 (Sherr and Roberts, 1995) . WAF1 can negatively regulate the G1-S transition by inhibiting the activity of cyclin-cdk complexes (Sherr and Roberts, 1995) . WAF1 has also been shown to be involved in the development of apoptosis (Waldman et al., 1996; Wang and Walsh, 1996; Gorospe et al., 1996) , and can inhibit SAPK activation (Shim et al., 1996) . The possible interrelationship between WAF1 and SAPK in the control of apoptosis is therefore another critical consideration in analyses of the control of apoptosis and cell cycle progression.
Etoposide (VP16), a DNA topoisomerase II (Topo II) inhibitor, is an important cancer chemotherapeutic agent with clinical activity against a broad range of human malignancies (Belani et al., 1994) . While VP16 has been demonstrated to induce apoptosis in a variety of tumor cell lines (Kaufmann, 1989; Lock and Stribinsiene, 1996; Lock et al., 1994; Mizumoto et al., 1994) , its eects upon or response to the proliferative signaling cascade has not been clari®ed. The evidence suggested that VP16-induced cytotoxicity is mediated by its interaction with the nuclear enzyme Topo II (Glisson et al., 1986; Davis et al., 1988) , although apoptosis in several tumor cell lines is neither directly related to Topo II protein level (Kataoka et al., 1994) nor associated with DNA strand breaks (Chresta et al., 1986) . In this communication, we analysed the ability of a set of oncogenes to alter the response of NIH3T3 cells to VP16 in apoptosis induction and alterations of signaling events and cell cycle molecules. We show that positvely acting oncogenes can enhance apoptosis induction and stress kinase activation by VP16.
Results
Induction of apoptosis by VP16 in oncogenic transformed but not in normal 3T3 cells
To investigate whether the sensitivity for apoptosis induction is dierent in transformed cells compared to their non-transformed parental cells, 3T3 cells and three clones stably transformed by dierent oncogenes (src, ras and raf) were treated with VP16 (10 mM) for various times. VP16 induced DNA fragmentation in all three transformed lines at 72 h after the treatment, but not in the untransformed 3T3 cells (Figure 1 ). The induction of apoptosis as assessed by DNA fragmentation was con®rmed by staining of the treated cells, where the nuclei became small and distorted, with condensed chromatin only in the transformed cells (Figure 2 ). Although some apoptotic cells fell o the coverslips, the most signi®cant morphological changes were still seen in Src cells (7/7), followed by Raf (13/35) and Ras cells (13/48). On the other hand, none of 3T3 cells (0/37) displayed this kind of morphological changes (Figure 2) . Similarly, the viability was lower in the transformed cells (Figure 3 ). This is especially pronounced at 72 h, where the dierence between 3T3 and Src and between 3T3 and Raf cells was statistically signi®cant (Figure 3) . Among the transformed cell lines, Src cells were most sensitive to apoptosis 
Induction of S-phase arrest by VP16 in oncogenic transformed cells
Alterations in cell cycle progression were next analysed. Arrest in S-phase was observed beginning 6 h following VP16 treatment in all four cell lines (Figure 4 ), as determined by¯ow cytometry. In 3T3 cells this arrest proceeded to late S-and G 2 /M by 12 h, with no further progression throughout the observation period. On the other hand, each of the transformed cell lines exhibited a substantial accumulation in mid-S-phase. This was most apparent in Src cells, followed by Raf and Ras cells, the same pattern as in the case of apoptosis. The kinetics of arrest in mid-S-phase during the treatment indicates that in the transformed cells the VP16 treatment must not have blocked passage from G 1 -to S-phase, rather it resulted in an incomplete and/or reversible blockage in S to G 2 /M phase. In addition, a population of cells with less DNA than G 1 cells (see Figure 4 ; 24 h Src panel) appeared in the cultures beginning after 24 h of treatment. Although these populations were seen in all four cell lines, they were most apparent in the src-transformed cells. Furthermore, a portion of src-transformed cells progressively became hyperploid (more DNA than G 2 /M phase cells) beginning 24 h after the treatment (see Figure 4 ; 72 h Src panel). Some of these sub-G 1 cells are likely to be apoptotic, as this is more evident in VP-16 treated transformed cells and is correlated with the extent of apoptosis induction (Figures 2 and 3) . Alternatively, the cells with DNA content less than G 1 or more than G 2 /M may re¯ect a phenomenon of uneven cell division during mitosis. While the appearance of cells with altered DNA content from normal might have been enhanced in transformed cells, the S-phase arrest by VP16 was clearly related to the oncogenic transformation.
It is interesting to note that while the individual characteristics of each transformed cell clone varied compared to the other transformed clones, as a group the three transformed clones responded much more similarly to each other than to the untransformed cells, despite the fact that each clone was transformed by a dierent oncogene. Clearly oncogenic transformation had altered the sensitivity to apoptosis induction and cell cycle arrest by VP16 in the NIH3T3 cells, and each of the activated members of the proliferative signaling pathway is able to induce a similar change. It would therefore appear that it is the action of the proliferative signaling pathway which is primarily responsible for the dierences seen between the transformed and untransformed cells. These observations are significant 
Stimulation of SAPK but not ERK by VP16
Since SAPK activation was demonstrated to play a role in apoptosis development induced by ceramide and NGF withdrawal (Verheij et al., 1996; Xia et al., 1995) and oncogenic ras was found to activate SAPK in some cases (Smeal et al., 1991; Clark et al., 1997) , attempts were made to investigate whether the apoptosis induced by VP16 in transformed cells is associated with changes of SAPK activation by VP16. As can be seen in Figure 5 , VP16 can strongly activate SAPK in transformed cells, with a maximal stimulation at 24 h after the treatment, followed by a gradual return to basal levels ( Figure   Figure 4 VP16 induces persistent S-phase arrest in transformed cells. The indicated cell lines were treated with 10 mM VP16 for the times listed prior to collection and analysed for the DNA content of individual nuclei by FACS analysis 5a). The extent of activation varied from 7.8-fold for raf-transformed cells to 22.4-fold for src-transformed cells; compared to a 4.1-fold increase in untransformed NIH3T3 cells. If at least 3.0-fold SAPK induction was considered as the minimal activation, the duration of SAPK activation was 66 h in Src cells, followed by 36 h in Raf and 24 h in Ras cells, whereas it was only 12 h in 3T3 cells. Although SAPK has been reported to be activated by dierent stimuli (Kyriakis and Avruch, 1996; Cano and Mahadevan, 1995) , these stimulations are normally shortlived, compared to the persistent activation of SAPK observed in these cells. For example, anisomycin, a well known and potent activating agent, stimulated SAPK activity within minutes after addition and continued for only 2 ± 4 h . Western blot analysis demonstrated that the increase in SAPK activity in transformed cells is not associated with signi®cant changes in the levels of the protein (JNK 1) itself within the cell (Figure 6 ). ERK1 activity, on the other hand, was only slightly activated following VP16 treatment (Figure 5b ) with no substantial dierence in the pattern between 3T3 and the transformed cells. Similar results have been reported in ceramide-mediated apoptosis in human U937 leukemia cells (Verheij et al., 1996) . These results demonstrated that VP16 can selectively activate SAPK but not ERK1 within 24 h of treatment. Whatever the role of SAPK in the development of apoptosis, however, it is clear that the action of each of these oncogenes contributed substantially to both the enhanced stress response and apoptosis induction in the cells responding to VP16 treatment.
Induction of WAF1 by VP16
WAF1, which is a potent inhibitor of cell cycle progression, has also been reported to inhibit SAPK activation (Shim et al., 1996) , apoptosis in myocytes (Wang and Walsh, 1996) , and prostaglandin A2-induced apoptosis in human carcinoma cells (Gorospe et al., 1996) . It was, therefore, important to determine if WAF1 expression might be responsible for any of the changes seen following VP16 treatment of transformed or untransformed cells. The same lysates previously used for SAPK and ERK1 assays were probed for WAF1 protein in Western blot analysis. WAF1 was induced beginning at 6 h after VP16 treatment and continued to be elevated for up to 72 h in all four cell lines (Figure 7) . A smaller band around 19 kd was also detected with this polyclonal antibody, and could be due to degradation of WAF1 protein or another cross reacting protein. Similar results were also described with g-radiation-induced WAF1 activation in BALB/C cells using the same source for the antibody (Poon et al., 1996) . Despite signi®cant WAF1 induction, there was no detectable changes in p53 protein level in these cells following the treatment (data not shown). These results demonstrated that WAF1 induction is an early event following VP16 treatment, and might be responsible for the S-phase arrest as described above. It is clear, however, that the expression of this protein is not likely to be involved in apoptosis development, since its induction was similar in the transformed and untransformed cells.
Discussion
The response of cells to anti-tumor drugs is in¯uenced by the action of signaling proteins (Thompson, 1995) .
In this study we demonstrate that the proliferative signal conferred by these three oncogenes along the ras pathway can increase apoptosis induction by etoposide. Previous studies have shown that c-Myc and E1A transformed cells are more susceptible to apoptosis induction by many factors, including anti-cancer drugs or treatments which restrict growth (Bissonnette et al., 1992; Fanidi et al., 1992; Evan et al., 1992; Hermeking and Eick, 1994; Teodoro et al., 1995; Lowe et al., 1994) . In some cases apoptosis development in transformed cells requires the presence of wild type p53 (Teodoro et al., 1995; Lowe et al., 1993 Lowe et al., , 1994 , is activated by IRF-1 (interferon regulatory factor 1) (Tanaka et al., 1994) , and inhibited by bcl-2 (Bissonnette et al., 1992; Fanidi et al., 1992) . On the other hand, p53-independent apoptosis has also been reported (Teodoro et al., 1995) . In addition, Ha-ras was found to be needed for serum-withdrawal or cancer drug-induced apoptosis in E1A transformed p53 +/+ mouse ®broblasts (Lowe et al., 1993 (Lowe et al., , 1994 . Clearly, the signaling mechanisms regulating the response of cells to cancer drugs are complex and interrelated. Our focus is upon the members of the ras pathway, which are primarily responsible for positive proliferative signaling within the cell. In these studies we demonstrated a decreased threshold for apoptosis induction by VP16 in NIH3T3 cells transformed by a single member of the proliferative signaling pathway. NIH3T3 cells transformed either by v-src, v-ras or vraf were induced by treatment with VP16 to undergo apoptosis, whereas the non-transformed NIH3T3 cells were not. Furthermore, the results with each oncogene were consistent with each other and distinct from the untransformed cells, suggesting that the presence of the proliferative signal, rather than the characteristics of any individual oncogene, was most critical to the results observed. This observation is of signi®cance since the action of these natural proliferative stimulatory genes is potentially involved in stimulating the growth of a wide variety of tumors. Clearly, any tumor must contain an activation of the positive proliferative signaling pathway to some extent, even though other alterations may also be involved in the tumor phenotype. Our data suggest that the presence of a continuous proliferative signal generated by members of the ras pathway might play a critical role in potentiating cells to undergo apoptosis in response to an anti-cancer drug.
These results were further extended by analysing the expression of other signaling proteins potentially involved in the control of apoptosis and/or cell cycle progression. The nature of the persistent SAPK activation by VP16 for 24 ± 26 h in the transformed cells might indicate its involvement in the apoptosis induction. It was proposed recently that the transient activation of SAPK may lead to proliferation, whereas the sustained activation causes apoptosis (Chen et al., 1996a) . Additional evidence for the possible role of SAPK activation in apoptosis comes from studies showing an increase in SAPK during NGF withdrawal, as well as ceramide-induced (Verheij et al., 1996; Xia et al., 1995) ; and g radiation-induced apoptosis (Chen et al., 1996a,b) , although this may not be the case in all cell lines (Liu et al., 1996 ) . While the correlation of enhanced SAPK activation with apoptosis induction by VP16 in the transformed cells is only suggestive of its potential role in VP16-induced apoptosis, this observation does clearly demonstrate that the proliferative signals conferred by this group of oncogenes can trigger a stronger stress response following VP16 treatment. This enhanced stress response may be critical for understanding of selective killing of tumor cells by anti-cancer drugs.
WAF1 can be activated both p53-dependently and p53-independently by DNA-damaging agents (Sherr and Roberts, 1995) . Furthermore, WAF1 has been reported to be involved in regulation of SAPK activity (Shim et al., 1996) and apoptosis development (Waldman et al., 1996; Wang and Walsh, 1996) . WAF1 protein increased in all four cell lines following VP16 treatment, regardless of transformation and apoptosis status (Figure 7) . Therefore, WAF1 induction is not associated with oncogenic transformation and could not account for the dierential response of transformed and non-transformed NIH3T3 cells to VP16 in terms of apoptosis. Rather, it may be responsible for S-phase arrest, which occurred in all four cell lines following 6 h treatment with VP16. Decrease in cyclin A-associated kinase activity at this time point con®rmed this speculation (Chen et al. unpublished observation) . Of interest, the S-phase arrest by VP16 was more pronounced in the transformed cells, despite the fact that WAF1 was induced similarly in untransformed and transformed cells (Figures 4 and 7) . These results would indicate that additional factors are involved in cell cycle progression in these cells after treatment with VP16.
Taken together, these results demonstrated that VP16 can induce apoptosis in three oncogenically transformed NIH3T3 lines, but not in the untransformed cells. The distinction was primarily between untransformed cells and cells transformed by any of the oncogenes, suggesting that the proliferative signal resulting from each of the oncogenes was of primary importance in apoptosis induction. Similar observation was recently made in enforced expressed E2F-1 cells, in which VP-16 was found to induce p53-independent apoptosis (Nip et al., 1997) . The potential role of SAPK in the induction of apoptosis extends to the fact that even among the three transformed lines, the extent of apoptosis, S-phase blockage, and SAPK induction were positively related. These data might provide an important clue in our understanding of the tumor speci®c killing potential of VP16. While this drug is believed to primarily target Topo IIa (Wang, 1996) , it is possible that the presence of a constitutive proliferative signal within a transformed cell also contributes in a critical way to the potentiation of cell killing. The possibility that proliferative signaling is directly involved in potentiating cancer drug killing is attractive since alterations in proliferative signaling are perhaps the most universal of all distinctions between normal and tumor cells.
Materials and methods

Materials
Dulbecco's Modi®ed Eagle Medium (DMEM) and calf serum were obtained from Celox (Hopkins, MN) and Sigma (Sigma, St Louis, MO), respectively. All other materials for cell culture were supplied by Gibco (GibcoBRL, Grand Island, NY). Rabbit anti-JNK1 (C-17) speci®cally recognizing p46 JNK1(SAPKg) and rabbit anti-JNK1 (full length SAPK) polyclonal antibodies were obtained from Santa Cruz Biotechnology (Santa Cruz, CA) and were used at a 0.5 mg/ml working concentration. These antibodies do not cross-react with ERK1 and ERK2 or other kinases such as MAPKAP K2. Rabbit anti-ERK1 (K-23) and Goat anti-WAF1 IgG (C-19) polyclonal antibody was also bought from Santa Cruz Biotechnology and used according to the Manufacturer's protocol. Antirabbit or anti-goat IgG conjugated with horse radish peroxidase ( 
Cell lines
NIH3T3 (3T3) cells and its sublines stably transformed by viral oncogene v-Src (Src), v-Ras (Ras) and v-Raf (Raf) have been maintained in DME medium containing 10% calf serum and antibiotics at 378C under the atmosphere of 5% CO 2 . The sources and properties of these cells have been previously described (Smith et al., 1986; Stacey et al., 1991) . In addition to the transformed morphology, the transformed phenotype was further con®rmed by reversion of the phenotype in Src and Ras but not Raf cells by microinjection of rasneutralizing monoclonal antibody Y13-259 as described previously (Smith et al., 1986) .
Cell culture and treatment
Cells were seeded at 5610 5 in a 100 mm petri dish with 10 ml growth media and were treated on the third day with 10 mM of VP16 or vehicle control for various time as indicated. At the end of the treatment cells both in suspension and those attached to the plate were washed twice with PBS and collected for dierent analysis, with one exception that only cells attached to the plate were stained with Hochest 33258 for apoptotic morphological changes.
Western blotting and kinase assay
Cells were lysed for 20 min on ice in modi®ed RIPA buer (50 mM Tris, pH 7.5, 150 mM NaCl, 1% NP-40, 0.25% sodium deoxycholate), which was supplemented with phosphotase inhibitors (1 mM EGTA, 5 mM NaF, 1 mM Na 3 VO 4 ) and the protease inhibitors (1 mM PMSF, 1 mg/ml of aprotonin, leupeptin and pepstatin) immediately before use. After centrifugation (13 000 g for 10 min at 48C) the supernatant was collected and used immediately for Western blotting, immunoprecipitation or stored at 7208C. Protein concentrations were determined by BioRad/DC Protein Assay Reagent (Biorad, Hercules, CA) with BSA dissolved in the same lysis buer as standard. An aliquot of 50 mg protein per lane was heated at 1008C for 5 min after mixing with an equal volume of 26SDS ± PAGE sample buer and loaded into a 7.5% acrylamide gel for JNK1 detection and a 12.5% acrylamide gel for WAF1. After electrophoresis, the gel was transferred to a nitrocellulose membrane (MSI, Westboro, MA) in transfer buer (30 mM Tris, pH 8.8, 120 mM glycine, 15% methanol and 0.05% SDS) on a semidry transfer apparatus from Biorad. The membrane was blocked with 5% non-fat milk in PBS containing 0.05% Tween prior to antibody treatments. The protein of interest was visualized with chemiluminescence.
For immunoprecipitation, 600 mg of protein was incubated with 1.5 mg of rabbit polyclonal anti-JNK1 (FL) or 2.0 mg of rabbit polyclonal anti-ERK1 (K-23) for 1 h at 48C in a rotating wheel. The immune complex formed was then precipitated by adding 30 ml of 50% protein A-sepharose beads in the RIPA buer and incubating for an additional 1 h at 48C. SAPK (Hibi et al., 1993) and ERK (Pages et al., 1993) assay was performed as described previously with slight modi®cations as described Hitomi et al., 1996) , respectively. Brie¯y, the agarose beads with bound kinases were washed two times in modi®ed RIPA buer and two times in HEPES binding buer (20 mM HEPES, pH 7.6, 50 mM NaXl, 0.05% Triton X-100, 0.1 mM EDTA and 2.5 mM MgCl 2 ). Supernatant above the sepharose beads was carefully removed and combined with 35 ml of kinase buer (20 mM HEPES, pH 7.6, 20 mM MgCl 2 , 20 mM ATP, 20 mM b-glycerolphosphate, 20 mM p-nitrophenyl phosphate, 0.5 mM Na 3 VO 4 2 mM DTT) and 5 mCi of [g- Western Reserve University) for SAPK or 6 mg of MBP (myelin basic protein) for ERK assay. The reaction was initiated by incubation at 308C for 30 min with occasional agitation. The reaction mixture was then mixed with equal volume of 26SDS ± PAGE sample buer and heated in a boiling water bath for 5 min before loading onto a 10% acrylamide gel (12.5% gel for ERK assay). The gel was dried and analysed in a phosphoimager.
DNA fragmentation
Cells were washed twice with cold PBS at the end of the treatment and lysed in buer containing 50 mM Tris-HCl, pH 8.0, 20 mM EDTA, 0.5% SDS, 0.2 mg/ml proteinase K. The lysates were then incubated at 508C for 1 h. The lysates were at this time either stored at 7208C or the DNA was immediately prepared as described (Liu et al., 1994) . DNA was extracted once with 0.7 ml phenol/ chloroform/isoamyl alcohol (IAA) (25/24/1) and once with 0.7 ml chloroform/IAA. DNA was then precipitated by adding isopropanol containing 0.625 M NaCl and 25 mg/ ml of glycogen and incubated at 7208C for 30 min. After pelleting at low speed, DNA was washed once with 80% ethanol, air-dried and dissolved in TE buer containing 100 mg/ml RNAase. After incubation at 378C for 2 h to digest RNA, DNA was measured spectrophotometrically and 20 mg DNA from each sample was separated on 2% agarose gel.
DNA staining for apoptosis
Cells on coverslips were washed and ®xed in 100% ethanol for 30 min at 7208C. The coverslips were incubated in 16Hoechst 33258 solution (0.1 mg/ml) for 10 min at room temperature, followed by successive washing with PBS and distilled water. The slides were mounted with antifade solution (Oncor, Inc., Gaithersburg, MD) and were visualized and photographed under u.v. light.
Determination of cell viability and¯ow cytometric analysis
Cells were washed with PBS, trypsinized and pooled with the cells collected from the corresponding suspension at the end of treatment. After washing once with PBS, cell pellets were resuspended in PBS. 50 ml of this cell suspension was mixed with an equal volume of 0.4% trypan blue solution. The viable (bright) and dead (blue) cells were counted by hemocytometer within 10 min and plotted as viability vs the time of VP16 treatment. After counting the remaining cells (45610 5 ) were spun and resuspended in crystalprotection medium (30% calf serum/10% DMSO) for¯ow cytometric analysis. After RNA digestion, DNA was stained with propidium iodide and analysed by FACSCAN¯ow cytometer (Becton Dickinson) for cell cycle distribution.
Abbreviations SAPK, stress-activated protein kinase (also called JNK); ERK, extracellular signal-regulated kinase; MAP kinase, mitogen-activated protein kinase; VP16, etoposide; Topo II, topoisomerase IIa.
